BIORESONANCE THERAPY IN THE ACTIVATION OF THE BACKUP FUNCTIONS OF THE BODY IN PATIENTS WITH TYPE 2 DIABETES

Aim. To analyze the effectiveness of bioresonance therapy in the treatment of patients with diabetes mellitus (DM) type 2 on the basis of clinical and biochemical signs and functional research methods. Material and methods. The study included the results of treatment of 413 patients with type 2 diabetes, which were divided into 3 comparable groups: 198 patients in the main group, 72 patients in the control group and 143 patients in the placebo group. In addition to pharmacotherapy, the main group received bioresonance therapy (BRT); the control group received only pharmacotherapy; the placebo group received pharmacotherapy and simulated BRT procedures. Such indicators like glycated hemoglobin (HbA1c), blood sugar before taking food, blood sugar 2 hours after eating, glucose in the urine, lipidogram, and body mass index (BMI), were evaluated on admission and 3 months after treatment for all patients. Results. After conducting bioresonance therapy, along with the pharmacotherapy of patients with type 2 diabetes in the main group, all the studied parameters: glycated hemoglobin (HbA1c; from 7.89 ± 0.06% to 5.89 ± 0.02%), fasting blood sugar (from 10.26 ± 0.09 mmol / l to 5.7 ± 0.02 mmol / l), blood sugar 2 hours after meals (from 13.28 ± 0.12 mmol /1 to 6.84 ± 0.04 mmol /1), glucose in urine (from 47.51 ± 0.97 mmol /1 to 0.50 ± 0.02 mmol /1), lipidogram and body mass index (from 30.09 ± 0.26 mmol /1 to 26.51 ± 0.18 mmol /1) was statistically significantly reduced compared with the control group and the placebo group. Conclusion. The research data and the dynamics of the treatment of the studied patients with type 2 diabetes indicate the effectiveness of using bioresonance therapy as one of the modern innovative methods in the complex treatment of patients with type 2 diabetes. BRT contributes to the activation offunctional reserves of the body, which leads to long-term compensation of diabetes.

type 2 diabetes mellitus, bioresonance therapy, basic therapy, glycemia, glycated hemoglobin, lipidogram, body mass index

1. Гончар В.Н. Сахарный диабет 2-го типа у лиц молодого возраста: этиология, патогенез, диагностика и лечение. Учебное пособие. / В.Н. Гончар, Е.Б. Башнина, Н.В. Ворохобина - СПб.: МАПО, 2012. - 22 с.

2. Бобровницкий И.П. Методологические аспекты разработки и внедрения новых технологий оценки и коррекции функциональных резервов в сфере восстановительной медицины / И.П. Бобровницкий // Курортные ведомости. - 2007. - №3 (42). - С.8-10.

3. Дедов И.И., Мельниченко Г.А. Эндокринология. Национальное руководство. / И.И. Дедов, Г.А. Мельниченко - М.: ГЭОТАР-Медиа, 2008. - 463 с.

4. Недосугова Т.В. Новые подходы к терапии сахарного диабета 2 типа / Т.В. Недосугова // Русский медицинский журнал. - 2006. - Т.14, №13. - С.2-5.

5. Кирьянова В.В. Динамика качества жизни больных сахарным диабетом 2 типа при использовании биорезонансной терапии / В.В. Кирьянова // Вестник Смоленской государственной медицинской академии. - Смоленск. - 2017. - Т.16, №2. - С.93-100.

6. Пономаренко Г.Н. Частная физиотерапия. / Г.Н. Пономаренко - М.: Медицина, 2005. - 266 с.

7. Холодова Е.А. Клиническая эндокринология: Руководство для врачей. / Е.А. Холодова - М.: ООО «Медицинское информационное агентство», 2011. 706 с.

8. Лихарев В.В. Методические рекомендации для медицинского прибора биорезонансной терапии «DETA -BRT». НПП «Эллис», 2006. - 102 с.

9. Мельниченко Г.А. Практическая медицина. / Г.А. Мельниченко М.: 2009. - 197 с.

10. Inzucchi S.E., Bergenstal R. M., Buse J. B., Diamant M., Ferrannini E., Nauck M., et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2012, Vol. 35(6), pp. 1364-1379.

11. Lionetti L., Mollica M.P., Lombardi A., Cavaliere G., Gifuni G., Barletta A. From chronic overnutrition to insulin resistance: The role of fat storing capacity and inflammation. Nutrition, Metabolism and Cardiovascular Diseases, 2009, No. 19(2), pp. 146-152.

12. Ryden L., Grant P.J., Anker S.D., Berne C., Cosentino F., Danchin N. et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European Heart Journal, 2013. No. 34(39), pp. 3035-87.